Trials / Completed
CompletedNCT00235482
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Viralytics · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.
Detailed description
Coxsackievirus A21, a naturally occurring enterovirus, has shown that in vivo it can infect and lyse melanoma. This study is to assess safety of a single intratumoural injection of the virus into an accessible subcutaneous melanoma metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Coxsackievirus A21 |
Timeline
- Start date
- 2005-11-08
- Primary completion
- 2006-04-21
- Completion
- 2006-04-21
- First posted
- 2005-10-10
- Last updated
- 2019-06-27
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00235482. Inclusion in this directory is not an endorsement.